Serine Protease Inhibitors Restrict Host Susceptibility to SARS-CoV-2 Infections.
A1AT
ATIII
COVID-19
PAI1
SARS-CoV-2
TMPRSS2
alpha-1-antitrypsin
antithrombin III
plasminogen activator inhibitor 1
serpin
Journal
mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231
Informations de publication
Date de publication:
28 06 2022
28 06 2022
Historique:
pubmed:
10
5
2022
medline:
1
7
2022
entrez:
9
5
2022
Statut:
ppublish
Résumé
The coronavirus disease 2019, COVID-19, is a complex disease with a wide range of symptoms from asymptomatic infections to severe acute respiratory syndrome with lethal outcome. Individual factors such as age, sex, and comorbidities increase the risk for severe infections, but other aspects, such as genetic variations, are also likely to affect the susceptibility to SARS-CoV-2 infection and disease severity. Here, we used a human 3D lung cell model based on primary cells derived from multiple donors to identity host factors that regulate SARS-CoV-2 infection. With a transcriptomics-based approach, we found that less susceptible donors show a higher expression level of serine protease inhibitors SERPINA1, SERPINE1, and SERPINE2, identifying variation in cellular serpin levels as restricting host factors for SARS-CoV-2 infection. We pinpoint their antiviral mechanism of action to inhibition of the cellular serine protease, TMPRSS2, thereby preventing cleavage of the viral spike protein and TMPRSS2-mediated entry into the target cells. By means of single-cell RNA sequencing, we further locate the expression of the individual serpins to basal, ciliated, club, and goblet cells. Our results add to the importance of genetic variations as determinants for SARS-CoV-2 susceptibility and suggest that genetic deficiencies of cellular serpins might represent risk factors for severe COVID-19. Our study further highlights TMPRSS2 as a promising target for antiviral intervention and opens the door for the usage of locally administered serpins as a treatment against COVID-19.
Identifiants
pubmed: 35532162
doi: 10.1128/mbio.00892-22
pmc: PMC9239148
doi:
Substances chimiques
Antiviral Agents
0
Plasminogen Activator Inhibitor 1
0
SERPINA1 protein, human
0
SERPINE1 protein, human
0
SERPINE2 protein, human
0
Serine Proteinase Inhibitors
0
Serpin E2
0
Serpins
0
alpha 1-Antitrypsin
0
Serine Endopeptidases
EC 3.4.21.-
TMPRSS2 protein, human
EC 3.4.21.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0089222Références
Nature. 2020 Nov;587(7835):619-625
pubmed: 33208946
Genome Biol. 2019 Dec 13;20(1):273
pubmed: 31836005
Nat Commun. 2021 Mar 19;12(1):1726
pubmed: 33741941
Vaccines (Basel). 2021 Apr 29;9(5):
pubmed: 33946736
Cytokine. 2021 Jan;137:155302
pubmed: 33002740
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Cell. 2015 Feb 12;160(4):631-643
pubmed: 25679759
Am J Physiol Lung Cell Mol Physiol. 2002 Feb;282(2):L226-36
pubmed: 11792627
Crit Care. 2009;13(5):R145
pubmed: 19740417
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
J Perinatol. 2008 Dec;28 Suppl 3:S127-35
pubmed: 19057604
Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16528-33
pubmed: 23012413
Nat Genet. 2021 Jun;53(6):801-808
pubmed: 33888907
J Clin Invest. 1989 Oct;84(4):1349-54
pubmed: 2794066
Hum Genet. 2021 Jun;140(6):969-979
pubmed: 33604698
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Nat Protoc. 2014 Jan;9(1):171-81
pubmed: 24385147
Am J Physiol Lung Cell Mol Physiol. 2015 Jun 15;308(12):L1189-201
pubmed: 25888573
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Nutr Metab Cardiovasc Dis. 2020 Oct 30;30(11):1914-1919
pubmed: 32907762
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Mol Cell. 2020 May 21;78(4):779-784.e5
pubmed: 32362314
Comput Struct Biotechnol J. 2020;18:4040-4047
pubmed: 33282147
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Biol Chem. 2021 Jan-Jun;296:100306
pubmed: 33476648
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
Genome Biol. 2014;15(12):550
pubmed: 25516281
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
Sci Signal. 2019 Nov 26;12(609):
pubmed: 31772123
FASEB J. 2020 Nov;34(11):14160-14165
pubmed: 32960480
N Engl J Med. 2020 Apr 9;382(15):1443-1455
pubmed: 32268028
Nat Commun. 2020 Nov 13;11(1):5761
pubmed: 33188185
Nature. 2021 Mar;591(7848):92-98
pubmed: 33307546
Respir Res. 2016 Jul 16;17(1):83
pubmed: 27423691
Nat Methods. 2019 Feb;16(2):163-166
pubmed: 30664774
Pathog Immun. 2021 Apr 26;6(1):55-74
pubmed: 33969249
Sci Rep. 2019 Mar 26;9(1):5233
pubmed: 30914743
Arch Bronconeumol (Engl Ed). 2020 Sep;56(9):609-610
pubmed: 33994645
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Proc Natl Acad Sci U S A. 2021 Mar 2;118(9):
pubmed: 33593941
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Mol Cell Proteomics. 2015 May;14(5):1265-74
pubmed: 25713122
Bioinformatics. 2020 Feb 1;36(3):964-965
pubmed: 31400197
J Vis Exp. 2010 Mar 26;(37):
pubmed: 20348870
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Antimicrob Agents Chemother. 2020 May 21;64(6):
pubmed: 32312781
BMC Med. 2020 Jul 15;18(1):216
pubmed: 32664879